Cubist Gains Option to Acquire Adynxx with Diversification in Mind
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 3 (Table of Contents)
Published: 4 Mar-2013
DOI: 10.3833/pdr.v2013.i3.1907 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Cubist Pharmaceuticals has acquired an exclusive option to buy San Francisco-based biotech Adynxx on completion of the Phase II study of the company’s lead compound AYX1 in acute post-surgical pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS